Risk factors for reporting adverse events and for study withdrawal in a population-based trial of vitamin D supplementation. Issue 197 (March 2020)
- Record Type:
- Journal Article
- Title:
- Risk factors for reporting adverse events and for study withdrawal in a population-based trial of vitamin D supplementation. Issue 197 (March 2020)
- Main Title:
- Risk factors for reporting adverse events and for study withdrawal in a population-based trial of vitamin D supplementation
- Authors:
- Malihi, Z
Wu, Z
Lawes, CMM
Sluyter, J
Waayer, D
Toop, L
Khaw, K-T
Camargo, CA
Scragg, R - Abstract:
- Highlights: Adverse events are routinely monitored in randomized controlled trials. However, the factors associated with adverse events have rarely been studied. We analyzed self-reported adverse events in a large vitamin D supplement trial. There was no pattern in the factors associated with self-reported adverse events. Adverse events were not associated with risk of withdrawal from the study. Abstract: With increasing numbers of randomized controlled trials (RCTs) investigating potential health events of vitamin D supplementation, a better understanding is required of the risk factors for adverse events and for study withdrawals. This analysis aimed to identify baseline risk factors of reporting an adverse event in a multi-year randomized double-blinded placebo-controlled trial of vitamin D supplementation. The secondary aim was to investigate if adverse events were associated with study withdrawals. We analyzed data from the Vitamin D Assessment (ViDA) study: 5110 adults, aged 50–84 years, living in Auckland, New Zealand. Monthly doses of 100, 000 IU vitamin D3 or placebo were mailed to participants homes, with a questionnaire to collect data on adverse events and adherence to the study capsule (initially monthly, then 4-monthly). Median follow-up was 3.3 years. Data were analysed using multivariable log-binomial regression and Cox-regression. During the follow-up period, 818 people reported adverse events and 412 withdrew or stopped returning questionnaires. Vitamin DHighlights: Adverse events are routinely monitored in randomized controlled trials. However, the factors associated with adverse events have rarely been studied. We analyzed self-reported adverse events in a large vitamin D supplement trial. There was no pattern in the factors associated with self-reported adverse events. Adverse events were not associated with risk of withdrawal from the study. Abstract: With increasing numbers of randomized controlled trials (RCTs) investigating potential health events of vitamin D supplementation, a better understanding is required of the risk factors for adverse events and for study withdrawals. This analysis aimed to identify baseline risk factors of reporting an adverse event in a multi-year randomized double-blinded placebo-controlled trial of vitamin D supplementation. The secondary aim was to investigate if adverse events were associated with study withdrawals. We analyzed data from the Vitamin D Assessment (ViDA) study: 5110 adults, aged 50–84 years, living in Auckland, New Zealand. Monthly doses of 100, 000 IU vitamin D3 or placebo were mailed to participants homes, with a questionnaire to collect data on adverse events and adherence to the study capsule (initially monthly, then 4-monthly). Median follow-up was 3.3 years. Data were analysed using multivariable log-binomial regression and Cox-regression. During the follow-up period, 818 people reported adverse events and 412 withdrew or stopped returning questionnaires. Vitamin D was not associated with reporting of adverse events. Of sociodemographic factors, ethnicity was associated with reporting adverse events: compared to European participants, Maori and Pacific Islander people were more likely to report an adverse event. Non-smokers were more likely to report an adverse event, compared to smokers (adjusted hazard ratio (HR) = 1.80; 95%CI = 1.24, 2.62); as were those who had reported a history of depression (adjusted HR = 1.27; 95%CI = 1.01, 1.60) or a recent cough or cold (adjusted HR = 1.22; 95%CI = 1.03, 1.44) at baseline. Reporting of adverse events was not associated with withdrawals (adjusted HR = 1.12; 95%CI = 0.86, 1.46). These data did not identify any clear pattern in the factors associated with self-reported adverse events, which themselves did not increase risk of withdrawals. … (more)
- Is Part Of:
- Journal of steroid biochemistry and molecular biology. Issue 197(2020)
- Journal:
- Journal of steroid biochemistry and molecular biology
- Issue:
- Issue 197(2020)
- Issue Display:
- Volume 197, Issue 197 (2020)
- Year:
- 2020
- Volume:
- 197
- Issue:
- 197
- Issue Sort Value:
- 2020-0197-0197-0000
- Page Start:
- Page End:
- Publication Date:
- 2020-03
- Subjects:
- Adverse events -- Longitudinal analysis -- Vitamin D supplementation -- Withdrawals
Steroid hormones -- Periodicals
Biochemistry -- Periodicals
Hormones -- Periodicals
Molecular Biology -- Periodicals
Hormones stéroïdes -- Périodiques
Steroid hormones
Periodicals
572.579 - Journal URLs:
- http://www.sciencedirect.com/science/journal/09600760 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.jsbmb.2019.105546 ↗
- Languages:
- English
- ISSNs:
- 0960-0760
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5066.850010
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 12736.xml